コレラ治療薬の世界市場:パイプラインレビュー(2019上半期)

【英語タイトル】Cholera - Pipeline Review, H1 2019

Global Markets Directが出版した調査資料(DATA906A090)・商品コード:DATA906A090
・発行会社(調査会社):Global Markets Direct
・発行日:2019年1月31日
・ページ数:47
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥212,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD6,000 ⇒換算¥636,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Cholera – Pipeline Review, H1 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Cholera – Pipeline Review, H1 2019, provides an overview of the Cholera (Infectious Disease) pipeline landscape.

Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Cholera – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 6 and 2 molecules, respectively.

Cholera (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cholera – Overview
Cholera – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cholera – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cholera – Companies Involved in Therapeutics Development
Akthelia Pharmaceuticals Ltd
Beijing Minhai Biotechnology Co Ltd
Napo Pharmaceuticals Inc
Cholera – Drug Profiles
AKT-10082 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera (trivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera (whole cell) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera [serotypes O1 + O139] (bivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera [strain O1/El/Tor/Ogawa] vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cholvax – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crofelemer DR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gram-negative bacterial infections vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMSUTMR-1501 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Cholera and Guillain-Barre Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cholera – Dormant Projects
Cholera – Discontinued Products
Cholera – Product Development Milestones
Featured News & Press Releases
Jun 13, 2018: Fast-acting Cholera Vaccine Could Curb Outbreaks
Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine
Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cholera, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Cholera - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2019
Cholera - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2019
Cholera - Pipeline by Napo Pharmaceuticals Inc, H1 2019
Cholera - Dormant Projects, H1 2019
Cholera - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Cholera, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

【掲載企業】

Akthelia Pharmaceuticals Ltd、Beijing Minhai Biotechnology Co Ltd、Napo Pharmaceuticals Inc

★調査レポート[コレラ治療薬の世界市場:パイプラインレビュー(2019上半期)] (コード:DATA906A090)販売に関する免責事項を必ずご確認ください。
★調査レポート[コレラ治療薬の世界市場:パイプラインレビュー(2019上半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆